Public Employees Retirement System of Ohio Takes $3.02 Million Position in Insulet Corporation $PODD

Public Employees Retirement System of Ohio bought a new position in shares of Insulet Corporation (NASDAQ:PODD) during the second quarter, HoldingsChannel reports. The fund bought 19,855 shares of the medical instruments supplier’s stock, valued at approximately $3,023,000.

A number of other institutional investors have also modified their holdings of the business. BlackRock Inc. acquired a new stake in Insulet during the 2nd quarter worth $1,018,582,000. State Street Corp raised its holdings in shares of Insulet by 2.1% in the fourth quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock valued at $896,916,000 after buying an additional 65,317 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Insulet by 2.1% in the fourth quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock valued at $568,274,000 after buying an additional 41,019 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Insulet by 10.5% during the fourth quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier’s stock worth $420,835,000 after buying an additional 141,167 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its stake in shares of Insulet by 462.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock worth $258,088,000 after buying an additional 1,011,369 shares during the period.

Analysts Set New Price Targets

Several brokerages recently issued reports on PODD. JPMorgan Chase & Co. restated a “neutral” rating and issued a $152.00 price target (down from $275.00) on shares of Insulet in a research report on Thursday, August 6th. Citigroup lifted their target price on Insulet from $165.00 to $172.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. William Blair assumed coverage on Insulet in a report on Wednesday, May 20th. They issued an “outperform” rating on the stock. UBS Group cut their price target on Insulet from $174.00 to $150.00 and set a “neutral” rating for the company in a research note on Thursday, August 6th. Finally, Leerink Partners downgraded Insulet from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $247.00 to $145.00 in a report on Thursday, August 6th. Fourteen analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Insulet has an average rating of “Hold” and a consensus target price of $195.40.

Insulet Stock Performance

Shares of PODD opened at $147.48 on Friday. The company has a 50-day simple moving average of $154.45 and a 200-day simple moving average of $177.72. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $10.23 billion, a PE ratio of 27.57, a P/E/G ratio of 1.19 and a beta of 1.08. Insulet Corporation has a 52-week low of $126.40 and a 52-week high of $354.88.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm had revenue of $801.70 million for the quarter, compared to the consensus estimate of $787.39 million. During the same quarter in the previous year, the firm earned $1.17 earnings per share. The firm’s revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. Equities research analysts predict that Insulet Corporation will post 6.51 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.